CA2131101A1 - Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents - Google Patents

Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents

Info

Publication number
CA2131101A1
CA2131101A1 CA002131101A CA2131101A CA2131101A1 CA 2131101 A1 CA2131101 A1 CA 2131101A1 CA 002131101 A CA002131101 A CA 002131101A CA 2131101 A CA2131101 A CA 2131101A CA 2131101 A1 CA2131101 A1 CA 2131101A1
Authority
CA
Canada
Prior art keywords
composition
compound
intraocular pressure
lowers
calcium antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002131101A
Other languages
English (en)
French (fr)
Inventor
Louis Desantis Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2131101A1 publication Critical patent/CA2131101A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002131101A 1992-05-13 1993-05-12 Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents Abandoned CA2131101A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88232892A 1992-05-13 1992-05-13
US882,328 1992-05-13

Publications (1)

Publication Number Publication Date
CA2131101A1 true CA2131101A1 (en) 1993-11-25

Family

ID=25380354

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002131101A Abandoned CA2131101A1 (en) 1992-05-13 1993-05-12 Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents

Country Status (5)

Country Link
EP (1) EP0639986A1 (ja)
JP (1) JPH07508030A (ja)
AU (1) AU4246793A (ja)
CA (1) CA2131101A1 (ja)
WO (1) WO1993023082A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686879B1 (fr) * 1992-02-05 1994-03-18 Adir Cie Nouveaux composes de 1,4-dihydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant.
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5733938A (en) * 1994-09-09 1998-03-31 Allergan Combination of levobunolol and dipivefrin for topical ophthalmic use
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
AU720326B2 (en) 1995-12-21 2000-05-25 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6225327B1 (en) 1996-04-18 2001-05-01 Alcon Laboratories, Inc. Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications
WO1997040834A1 (fr) * 1996-04-26 1997-11-06 Fujisawa Pharmaceutical Co., Ltd. Agents ameliorant la circulation peripherique pour tissus ophthalmiques contenant des dihydropyridines
WO1997045118A1 (fr) * 1996-05-27 1997-12-04 Otsuka Pharmaceutical Co., Ltd. Agents ameliorant le flux sanguin ophtalmovasculaire et agents protecteurs des papilles optiques
CA2270119A1 (en) 1996-10-28 1998-05-07 Senju Pharmaceutical Co., Ltd. Drugs for ameliorating ocular circulatory disorders
IT1295423B1 (it) * 1997-10-10 1999-05-12 Medivis S R L Uso della flunarizina nella terapia topica del glaucoma
ES2224597T3 (es) 1998-01-29 2005-03-01 Akzo Nobel N.V. Agentes que mejoran la circulacion optica papilar.
WO2000057914A1 (fr) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Agents permettant d'abaisser la tension oculaire
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
CA2369299A1 (en) * 1999-04-14 2000-10-19 Senju Pharmaceutical Co., Ltd. Inhibitor of visual function disturbance caused by optic nerve cell disorder due to factor other than ophthalmic circulatory disorder
WO2001041756A2 (en) * 1999-12-02 2001-06-14 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
EP1265903B1 (en) * 2000-03-23 2004-05-12 Ortho-Mcneil Pharmaceutical, Inc. Thiepino[3,2-b]dihydropyridines and related compositions and methods
WO2001092267A2 (en) * 2000-05-30 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. Dihydropyridine compounds for the inhibition of calcium-influx
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
US20050176822A1 (en) * 2002-03-28 2005-08-11 Naoto Hanyu Phenylacetonitrile derivatives and hair tonics and external preparations for skin containing the derivatives
WO2004045644A1 (ja) 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
WO2004069275A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation 眼科用剤
JP5576659B2 (ja) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Ｔｒｋレセプター調節因子の使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2577802B1 (fr) * 1985-02-26 1987-07-24 Synthelabo Compositions pharmaceutiques a base de betaxolol et de nifedipine
FR2585574B1 (fr) * 1985-07-31 1988-09-09 Corbiere Jerome Nouvelles compositions pharmaceutiques anti-glaucomateuses a base de 1,4-dihydropyridines et leur procede d'obtention
FR2593395A1 (fr) * 1986-01-28 1987-07-31 Corbiere Jerome Nouvelles compositions pharmaceutiques antiglaucomateuses a base de 3-acetoxy-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-one ou d'un de ses sels et leur procede d'obtention
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物

Also Published As

Publication number Publication date
WO1993023082A1 (en) 1993-11-25
EP0639986A1 (en) 1995-03-01
AU4246793A (en) 1993-12-13
JPH07508030A (ja) 1995-09-07

Similar Documents

Publication Publication Date Title
CA2131101A1 (en) Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
AU720326B2 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
DE69733611T2 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
JP2009298808A (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
JPH10503470A (ja) 減少した粘度を有する眼科治療用組成物
JPH09104626A (ja) 物質の濫用による離脱症状の治療剤
JP2002527392A (ja) 末梢的に作用する抗掻痒アヘン剤
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
AU704938B2 (en) Combination therapy for treating glaucoma
JPH07504915A (ja) ムスカリン拮抗物質投与による，哺乳動物の眼における眼内圧低下法
KR20010021854A (ko) 말초 작용성 항소양성 아편제
McLAUGHLIN et al. A synopsis of recent developments in antiglaucoma drugs
AU2001278708A1 (en) Adenosine derivatives and use thereof
CA2164733A1 (en) Methods and compositions for lowering intraocular pressure
WO2019131901A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬製剤
US4617306A (en) Pharmaceutical preparation comprising co-dergocrine and a calcium antagonist
CA2240271C (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
CN111479568A (zh) 司培前列素与Rho激酶抑制剂的组合药物
WO1998014193A1 (en) The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain
CA2324116A1 (en) Nk-1 receptor antagonists and eletriptan for the treatment of migraine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead